Introduction
Tibolone (Livial) is a synthetic steroid that has been used extensively for the prevention of postmenopausal osteoporosis [1, 2] and for the treatment of climacteric symptoms [3] . It is the prototype of a compound that acts as a selective tissue estrogen activity regulator (STEAR) [4] . A key element in this tissue specific regulation of estrogen activity is mediated through enzymatic mechanisms that activate or inactivate estrogenic compounds prior to their interaction with a steroid receptor [5] . metabolized into three biologically active metabolites. The 3␣-hydroxytibolone (3␣-OH-tibolone) and 3␤-hydroxytibolone (3␤-OH-tibolone) metabolites have estrogen agonist properties, and the 4 -ketoisomer has progestogenic and androgenic effects. Sulfation of the hydroxytibolone metabolites by sulfotransferase enzymes (SULTs) renders these metabolites receptor-inactive and reduces their estrogenic effects. SULT activity may account for the clinical effects of tibolone treatment that include an unchanged mammographic breast density in most women, less symptoms related to the breast, and less vaginal bleeding when compared with usual hor-0039-128X/$ -see front matter © 2005 Elsevier Inc. All rights reserved. doi:10.1016/j.steroids.2005.11.003 mone replacement therapy [6] [7] [8] [9] [10] . An additional protective effect of tibolone in these tissues is the inhibition of sulfatase activity by the tibolone metabolites in breast and endometrial cells [5, 11] . By contrast, the lack of steroid SULT activity and minimal inhibition of sulfatase activity by tibolone in bone cells allow free hydroxytibolone metabolites to activate the estrogen receptor (␣) in bone and to decrease bone resorption [5, 11] . Thus, tibolone, as a STEAR, does not behave as a selective estrogen receptor modulator (SERM), but rather acts by enzymatic pre-receptor regulation of the estrogenic active metabolites.
Sulfated hydroxytibolone metabolites have been found in the circulation, supporting the involvement of SULTs in the regulation and metabolism of tibolone. In the cytosolic SULT superfamily there are at least 10 human SULT genes [12] . Fusion proteins of two steroid SULTs expressed in bacteria have been shown to use tibolone metabolites as substrates [13] . However, the exact SULT isozymes involved in the sulfation of the active tibolone metabolites in postmenopausal human liver and other tissues have yet to be fully characterized.
In this study we tested samples of human premenopausal and postmenopausal liver and small intestine for SULT activities with tibolone metabolites. We then used postmenopausal liver to establish biochemical properties and radiochemical assays with the substrates 3␣-OH-tibolone and 3␤-OHtibolone. These tools allowed us to document the postmenopausal liver contribution to the sulfation of hydroxytibolone metabolites. Because the cytosolic liver preparation represented a composite of SULT activities, we also compared the kinetic parameters of cDNA expressed SULT activities to the liver SULT activities when tested with the tibolone metabolites. 
Experimental

Materials
Tissue samples and cytosol preparations
Both the IRB and the Research and Development Committee of the VA-Nebraska Western Iowa Health Care System approved these studies. Frozen human liver premenopausal (37.8 ± 6.3 years, mean ± S.D., n = 5) and postmenopausal (69.1 ± 7.4 years, mean ± S.D., n = 10) samples, and small intestine premenopausal (39.2 ± 5.4 years, mean ± S.D., n = 5) and postmenopausal (71 ± 10 years, mean ± S.D., n = 11) samples were obtained from the National Disease Research Interchange (NDRI). All samples were obtained from Caucasian subjects at autopsy except for one premenopausal liver surgical sample and two premenopausal small intestine surgical samples. Tissue was stored at −80 • C until preparation. Tissue samples were homogenized for 15-30 s in four volumes of 2.5 mM DTT, 1.25 mM disodium EDTA in 5 mM potassium phosphate buffer, pH 7.5, with a Polytron Tissue Homogenizer (Kinematica, Lucerne, Switzerland). Homogenates were centrifuged at 12,900 × g for 10 min at 4 • C. The supernatant was removed and centrifuged at 100,000 × g for 1 h at 4 • C. Aliquots of the high speed supernatant (HSS) were stored at −80 • C until assay. Equal volumes of each HSS were pooled for each tissue. COS-1 cells were transfected with SULT cDNA and processed by our previously published procedures [19] [20] [21] [22] . 
RNA extraction and RT-PCR
Sulfotransferase (SULT) and protein assays
SULT activities were measured by the method of Foldes and Meek [25] , as modified by Anderson and Liebentritt [26] . Optimal conditions with hydroxytibolone as the substrate were established with regard to pH, protein and substrate concentrations. Assays with the hydroxytibolone substrates were performed with 2.5 and 3.5 g protein per assay tube for the liver pool HSS and the small intestinal HSS, respectively. SULT1E1 and SULT2A1 were assayed with 1.1 and 0.7 g protein per assay tube, respectively. The final concentrations used in the assays were 1 M 3␣-OH-tibolone and 4 M 3␤-OH-tibolone with liver and small intestinal HSS and 1 M hydroxytibolone substrates for the activity screen of expressed SULT enzymes. The pH values for potassium phosphate buffers at a final concentration of 8.3 mM were 7.5 for the liver and small intestine, 6.5 for expressed SULT1E1 with hydroxytibolone, and 6.0 for expressed SULT2A1 with 3␣-OH-tibolone and 7.0 with 3␤-OH-tibolone. A MgCl 2 concentration of 1.0 mM was used with hydroxytibolone metabolite assays and 0.3 mM in assays with estrone (SULT1E1) and DHEA (SULT2A1) as substrates. Assays of tissue SULT1A1, 1A3, 1E1 and 2A1 activities were performed with their respective model substrates as previously published [19, 27] . Reactions were incubated at 37 • C for 30 min and blank samples containing no sulfuryl group acceptor substrate were used as controls. Radioactivity was measured using a Packard model 1600 TR liquid scintillation counter. One unit of enzyme activity represented the formation of 1 nmol of sulfated product per hour of incubation at 37 • C. Assays were performed in triplicate and values reported are the means of three determinations unless otherwise specified. Protein concentrations were measured by the dye binding method of Bradford [28] with BSA as the standard.
Thermal stability
Thermal stability of enzyme activities was tested by the methods of Reiter et al. [29] as modified by Anderson et al. [26, 30] . Aliquots of diluted HSS were pre-incubated for 15 min at various temperatures prior to assay. Aliquots of the same diluted preparation were kept on ice as a control. Each aliquot was then assayed for SULT activity.
HPLC
HPLC analyses were performed at room temperature using a Waters RP18 3. 
Data analysis
Apparent K m and V max values were calculated by the direct linear plot method of Eisenthal and Cornish-Bowden [31] using the Enzpak 3 program by Williams (Elsevier-Biosoft, Cambridge, UK). The 50% inactivation temperature (T 50 ), 50% inhibition concentration (IC 50 ) with DCNP and percentage of increased activity with NaCl were determined using a curvefitting program. Linear regression analysis was done by the Spearman rank correlation method for non-parametric statistics (Prism3, GraphPad Software, San Diego, California).
Results
RT-PCR detection of human SULT expression
Reverse transcription-polymerase chain reaction (RT-PCR) experiments were performed with total RNA extracted from individual premenopausal and postmenopausal human livers and SULT gene-specific primers for SULT1A1, 1A3, 1E1, 2A1, 2B1 v1 and 2B1 v2. Liver and small intestinal samples were tested to confirm whether mRNA predicted the presence of activity for SULT1E1 and SULT2A1. SULT1A1, SULT1E1 and SULT2A1 mRNAs were expressed in all 10 postmenopausal liver samples (Fig. 1) . In separate studies of mRNA expression, SULT1A3 was present in all liver samples and SULT2B1 v2 mRNA was expressed in seven samples, while SULT2B1 v1 mRNA was not detected in any of the liver samples (data not shown). Six individual postmenopausal small intestinal samples were tested as a representative sampling. All were positive for SULT1A1, five of six were positive for SULT1A3 and only two samples were both positive for SULT1E1, SULT2A1 and SULT 2B1 v2 (data not shown).
Postmenopausal human liver SULT activities with tibolone metabolites
A pool of the postmenopausal liver HSS was used to characterize SULT activities with hydroxytibolone substrates. Human liver SULT activities with hydroxytibolone increased in a linear fashion with HSS protein up to at least 25 g protein per assay. The chosen final HSS protein of 2.5 g was within the linear range of activity. Optimal SULT activities were found with potassium phosphate, pH 7.5. Magnesium increases the activities of several SULT enzymes [15, 19] . Therefore, MgCl 2 concentrations of 1.0-16 mM were tested in the assay. A final MgCl 2 concentration of 1.0 mM increased SULT activities by 9.2% with 3␣-OH-tibolone and by 6.2% with 3␤-OH-tibolone. Subsequent liver and small intestine SULT assays with hydroxytibolone were performed at pH 7.5 with 1.0 mM MgCl 2 .
Effects of varying hydroxytibolone and PAPS concentrations
The effect of a range of hydroxytibolone concentrations on SULT activities was determined (Fig. 2) . When hydroxytibolone concentrations were evaluated from 16 pM to 128 M, substrate inhibition occurred at concentrations above 2 M 3␣-OH-tibolone and 4 M 3␤-OH-tibolone. Apparent K m values for postmenopausal human liver SULTs with hydroxytibolone were calculated from the means of three experiments with each substrate ( Table 1 ). The optimal concentrations of hydroxytibolone used in subsequent assays of liver and small intestine SULTs were 1 M 3␣-OH-tibolone and 4 M 3␤-OHtibolone.
The effect of varying 
Effects of temperature, DCNP inhibition and sodium chloride
Assays were conducted to compare the thermal stability, DCNP inhibition and the effect of NaCl on postmenopausal human liver SULT activities with hydroxytibolone substrates. Thermal stability is a sensitive indicator of differences in protein struc- ture [29] . The patterns of tissue SULT thermal stability when assayed with tibolone might indicate which isozyme was involved. The thermal stability of human liver SULT activities was determined with hydroxytibolone after pre-incubation of tissue aliquots for 15 min at temperatures from 35 to 47 • C (Table 1) .
Another approach to the characterization of SULT isozymes is the response to the inhibitor DCNP. Human postmenopausal liver SULT activities assayed with hydroxytibolone were mea- (Table 1) . IC 50 values for SULT activities with DCNP were similar. NaCl enhances SULT1E1 and SULT2A1 activities when assayed with the model substrates estrone and DHEA [15, 19] . In our study, activation was present when the postmenopausal human liver pool was assayed with hydroxytibolone as the substrates in the presence of NaCl ( Table 1 ). The activation was consistent with the behavior of steroid SULTs 1E1 and 2A1, as opposed to inhibition by NaCl that occurs with SULT1A1 and SULT1A3 [27] .
Expressed SULT activity with tibolone metabolites
Expressed SULT1E1 and SULT2A1 demonstrated excellent activities when screened with assays using 1 M hydroxytibolone as the substrates. Expressed SULT1A1, SULT1A2, SULT1A3, SULT1C2, SULT2B1 v1 and SULT2B1 v2 assayed with the same substrates showed no detectable activities (Fig. 3) . Further investigation of expressed SULT1E1 and SULT2A1 was done to determine optimal assay conditions and apparent K m values with the tibolone metabolites ( Table 1) . These values were equivalent to the apparent K m values obtained with the postmenopausal liver preparations.
Product identification by HPLC
Radiolabeled hydroxytibolone products were prepared with the optimized assay, separated with reversed phase HPLC and compared to standards. The radiolabeled products of sulfation by postmenopausal liver SULTs, expressed SULT1E1 and SULT2A1 co-eluted with the 3␤-sulfate-hydroxytibolone standards exclusively when 3␤-OH-tibolone was the substrate. A major product peak that was produced when 3␣-OH-tibolone was assayed with each SULT preparation co-eluted with the 3␣-sulfate-hydroxytibolone standard. In assays with only the liver and expressed SULT2A1 there was a second smaller peak that was not identified because it did not co-elute with any of the available standards.
Individual liver activities with tibolone metabolites
To assess the tissue specific activity of liver SULTs and their contributions to sulfation of tibolone metabolites, individual premenopausal and postmenopausal liver samples were assayed with 25 nM estrone (SULT1E1), 5 M DHEA (SULT2A1), 1 M 3␣-OH-tibolone and 4 M 3␤-OH-tibolone as the substrates. (Figs. 4 and 5) . Activities with the premenopausal livers were 0.6 with estrone (n = 2), 3.1 ± 0.8 with DHEA (n = 5), 2.9 ± 0.9 with 3␣-OH-tibolone and 4.0 ± 1.3 with 3␤-OH-tibolone (both n = 5, units/mg protein, mean ± SEM, Fig. 4) . Each activity measured with DHEA or hydroxytibolone as the substrates was higher than the activity with estrone. SULT activities of the postmenopausal livers were <0.05 (n = 10) with estrone (SULT1E1), 1.8 ± 0.3 (n = 8) with DHEA (SULT2A1), 0.6 ± 0.1 and 0.9 ± 0.2 with 3␣-OH-tibolone and 3␤-OH-tibolone, respectively (n = 8) (units/mg protein, mean ± SEM, Fig. 5 ). Samples with undetectable SULT1E1 activity were tested with EMATE, a sulfatase inhibitor. Sulfatase activity would degrade the radiolabeled product and obscure the presence of SULT activity. There were no increases in measured SULT1E1 activity in the presence of EMATE. In addition, there was no relationship between the SULT1E1 tissue activities and time from death to autopsy to explain loss of activity, but the sample number was small (data not shown). The internal liver standard used to monitor SULT1E1 assays was a pool of samples from three male donors. The SULT1E1 activity was several-fold higher than postmenopausal samples and the liver HSS pool stored at −80 • C retained activity throughout the 2 years of this study.
Small intestine activities with tibolone metabolites
Human gastrointestinal tissue contains multiple SULT enzymes that include SULTs 1A1, 1A3, 1E1 and 2A1 [32] . These enzymes are differentially distributed throughout the gut [33] and they contribute to the metabolism of hydroxytibolone metabolites within the intestine. We tested both premenopausal and postmenopausal small intestinal HSS samples for SULT activities in pooled preparations with the same substrate concentrations used with the liver samples. SULT1A1 activities of 2.7 and 0.2 units/mg protein were present in premenopausal and postmenopausal samples, respectively, and SULT1A3 activities were 12.8 and 0.2 units/mg protein with premenopausal and postmenopausal samples, respectively. Activities with the premenopausal small intestinal pool (n = 4) were <0.1 units/mg protein with estrone (SULT1E1) and 0.2 units/mg protein with DHEA (SULT2A1). Activities with the postmenopausal small intestinal pool (n = 6) were not detectable with estrone or DHEA. Mean activities of three individual samples with measurable levels were 0.03 ± 0.01 with 3␣-OH-tibolone and 0.04 ± 0.01 with 3␤-OH-tibolone (units/mg protein, mean ± SEM). It was not possible to determine the exact location of the intestinal tissue samples to discern whether the sampling itself contributed to the differences observed. The mean SULT2A1 activity of the two premenopausal surgical small intestine samples was similar to the higher SULT2A1 activity of one of the three premenopausal autopsy samples. Other premenopausal surgical small intestinal SULT activities showed no distinct patterns that distinguished them from autopsy small intestinal sample activities. In these small groups, there were no trends of negative correlations between SULT activities and length of time from death to autopsy in liver or small intestine (r = 0.0, n = 8 for postmenopausal livers; no meaningful trend was evident for the three small intestinal samples with activity).
Discussion
Tibolone represents the initial steroid in the class of agents identified as selective tissue estrogen activity regulators (STEAR) [4] . This study is the first systematic investigation of human postmenopausal tissue sulfation of tibolone metabolites as one of the tissue-specific components in the prereceptor enzymatic regulation of the estrogenic effects of tibolone. We have identified human premenopausal and postmenopausal liver and small intestine SULT activities involved in the sulfation of the hydroxytibolone metabolites. Assays established for these activities represented a combination of SULT activities because of the documented presence of multiple SULTs in these tissues [32] [33] [34] . Biochemical properties found for postmenopausal liver SULTs with the tibolone metabolites as substrates were similar to those described with cDNA-expressed human SULT1E1 and SULT2A1 activities (Table 1) . For example, the apparent K m values for the postmenopausal liver SULTs and expressed SULT1E1 with 3␣-OH-tibolone as the substrate were 0.18 M for each preparation. Apparent K m values for all three preparations assayed with 3␤-OH-tibolone were essentially the same, from 0.42 to 0.56 M. The individual liver activity data and HPLC analyses of assay products with normal and postmenopausal livers and expressed SULT preparations indicated that SULT2A1 was the major contributor to the sulfation of 3␣-OH-tibolone and 3␤-OH-tibolone. Liver SULT2A1 activities measured with DHEA as the substrate varied 3.7-fold in the premenopausal samples and 23-fold in the postmenopausal samples. Previous studies of human female surgical samples have documented a four-fold variation in liver SULT2A1 activity [34] and a 15-fold variation in small intestine SULT2A1 immunoreactive protein [32] . Genetic polymorphisms of SULT2A1 associated with decreased activity have been described only in African American subjects [35] . Effects of such polymorphisms are unlikely in our samples because they were all obtained from Caucasian subjects. Other reasons for SULT2A1 variability in our samples include changes in activity due to sample handling prior to assay or differences in sample location within the small intestine that would reflect the variable distribution of SULT activities within the gastrointestinal tract [33] . There were no trends to support an association of SULT2A1 activities with the length of time from death to autopsy in our limited number of liver and small intestinal samples. However, the ability to accurately designate the location of the small intestinal sample acquisition supported the use of surgical tissue in future studies. The potential effects, if any, of SULT2A1 activity variations upon intra-hepatic or small intestinal regulation of responses to hydroxytibolone metabolites are not known.
Individual liver SULT1E1 activities were low in both premenopausal and postmenopausal samples. Two of the five premenopausal samples contained substantial SULT1E1 activity and four of the 10 postmenopausal samples contained SULT1E1 activity that was just above the limit of detection for the assay (Figs. 4 and 5) . SULT1E1 activity was undetectable in the remaining samples. Reasons other than sample handling for the variations include SULT1E1 genetic polymorphisms that lead to decreased enzyme activity and immunoreactive protein [36] or alterations in the tissue hormonal environment [37] . Our samples were not genotyped for the SULT1E1 allozymes, but this approach in a larger sample of postmenopausal tissues might assist in explaining variations. Changes in SULT1E1 levels have been documented in endometrial tissue as a result of cycling progesterone in premenopausal women and also in women on oral contraceptives that contain progestational agents [37, 38] . To address the possibility that the SULT1E1 activities in liver and small intestine might change with the variations in the local hormonal milieu, future studies of these tissues from women will require detailed information about their hormonal status.
This report has established the radiochemical enzymatic assay for human postmenopausal liver SULT activities with hydroxytibolone substrates, characterized the SULT biochemical properties with these substrates and identified SULT2A1 as the major contributor to sulfation of these metabolites in postmenopausal tissue. Our documentation of the tissue SULT activities and the resulting sulfated hydroxytibolone metabolites supports the occurrence of pre-receptor enzymatic regulation of estrogen compounds. The results provide a basis for further investigation of the tissue-selective regulation of tibolone effects and emphasize the complexity of steroid hormone sulfation.
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